Pipeline — Biologic Therapeutic Candidates
EirGenix's biologics pipeline includes monoclonal antibody biosimilars, antibody-drug conjugate (ADC) candidates, and a hyaluronidase program supporting subcutaneous drug delivery. The table below outlines each program's indication, target, development stage, and partner.
| PRODUCT | DRUG CLASS | INDICATION | TARGET | PROGRESS | PARTNER | |||
|---|---|---|---|---|---|---|---|---|
| PRE-CLINICAL | PHASE I | PHASE II/III | MAA/BLA | |||||
EG12014* (EIRGASUN® / HERWENDA®) Trastuzumab biosimilar | Monoclonal Antibody | HER2+ Breast Cancer (BC) | HER 2 |  |  | |||
EG1206A Pertuzumab biosimilar | Monoclonal Antibody | HER2+ BC | HER 2 | *Phase III Waived | | |||
EG12043 (TSY110) Kadcyla biosimilar | Antibody Drug Conjugate (ADC) | HER2+ BC | HER 2 | |  | |||
EG13084 TRZ+PTZ (SC formulation) | Monoclonal Antibody | HER2+ BC | HER 2 | | - | |||
EG12112 Immuno-oncology biosimilar | Monoclonal Antibody | Solid Tumors | PD-L1 | | - | |||
EG12164/EG12184 Hemato-oncology biosimilar | Monoclonal Antibody | Myeloma | CD38 | | - | |||
EG7412F Hyaluronidase (rHuPH20) | SC Enabling Enzyme | N/A | High-dose mAb forms. | | - | |||
EG12170 ADC biosimilar | Antibody Drug Conjugate | HER2+ BC | HER 2 | | ||||